公开(公告)号：EP1483247B1

公开(公告)日：2009-06-24

申请号：EP03719019.6

申请日：2003-03-13

申请人： EURO-CELTIQUE S.A.

发明人： GOEHRING, R., Richard ,  VICTORY, Sam, F. ,  KYLE, Donald, J.

IPC分类号： C07D239/46 ,  C07D239/32 ,  A61K31/505 ,  A61P25/00

CPC分类号： C07D239/42 ,  C07D239/47

摘要： This invention relates to a method of treating disorders responsive to the blockade of sodium ion channels using novel aryl-substituted pyrimidine compounds of Formula (I): or a pharmaceutically acceptable salt, or solvate thereof, wherein A, R1, R2, R3 and R4 are defined in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

公开(公告)号：EP1509523B1

公开(公告)日：2009-01-21

申请号：EP03741857.1

申请日：2003-06-02

申请人： EURO-CELTIQUE S.A.

发明人： CHEN, Zhengming ,  VICTORY, Sam, F.

IPC分类号： C07D471/10 ,  A61K31/4465 ,  A61P29/00

CPC分类号： C07D471/10

摘要： Triazaspiro Compounds, compositions comprising a Triazaspiro Compound, methods for treating or preventing pain in an animal comprising administering to an animal in need thereof an effective amount of a Triazaspiro Compound and methods for stimulating opioid-receptor function in a cell comprising contacting a cell capable of expressing an opioid receptor with an effective amount of a Triazaspiro Compound are disclosed.

公开(公告)号：EP1483247A2

公开(公告)日：2004-12-08

申请号：EP03719019.6

申请日：2003-03-13

申请人： Euro-Celtique S.A.

发明人： GOEHRING, R., Richard ,  VICTORY, Sam, F. ,  KYLE, Donald, J.

IPC分类号： C07D239/46 ,  C07D239/32 ,  A61K31/505 ,  A61P25/00

CPC分类号： C07D239/42 ,  C07D239/47

摘要： This invention relates to a method of treating disorders responsive to the blockade of sodium ion channels using novel aryl-substituted pyrimidine compounds of Formula (I): or a pharmaceutically acceptable salt, or solvate thereof, wherein A, R1, R2, R3 and R4 are defined in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.